Haploidentical hematopoietic stem cell transplantation as promising therapy in the improved survival of pediatric patients with leukemias and myelodysplasias

Table 1 Methodological aspects: General characteristics on the studies included

Ref.	Journal	Country	Study designs	Study analysis time	Objective
Kim et al[15], 2021	British Journal of Haematology	Korea	Retrospective	2009-2020	To analyze genetic abnormalities in JMML to evaluate the genetic profile of this rare paediatric leukaemia in a single Korean institution
Hong et al[16], 2022	Transplan tation and Cellular Therapy	Korea	Retrospective comparative	2013-2020	To compare outcomes in children and adolescents with high-risk acute leukemia after a busulfan-based myeloablative conditioning regimen along with HRD HSCT with PT-Cy or MUD HSCT
Bertaina et al[17], 2018	Blood	Italy	Retrospective	2010-2015	To report the outcome of children with acute leukemia who received either UD-HSCT or αβhaplo-HSCT
Bai et al[18], 2020	Leukemia Research	China	Retrospective	2008-2018	To investigate the clinical characteristics, outcomes, and effects of HSCT (especially haplo-HSCT) among non- infant children with t(v;11q23)/MLL-r B-ALL
Ruggeri et al[19], 2021	Transplan tation and Cellular Therapy	Italy	Prospective cohort	2011-2019	To analyze the outcomes of unmanipulated haploidentical Transplantation using PT-Cy in pediatric patients with acute lymphoblastic leukemia
Sun et al[20], 2015	European Review for Medi cal Pharmaco logical Sciences	China	Retrospective	2002-2012	To discuss the effect of transplantation and the difference in treatment effect among children having different donor patterns, aiming to identify the prognostic factors
Sano et al[21], 2021	Frontiers in pediatrics	Japan	Retrospective	2009-2019	To aimed to evaluate the efficacy of T-cell replete HLA-HSCT for pediatric RR-BCP-ALL
Paina et al[22], 2018	Cellular Therapy and Transplantation	Germany	Prospective cohort	2006-2016	To assess efficiency of haplo-HSCT performed with non-manipulated grafts of children and adolescents with high-risk acute leukemias. In this respect an efficiency study of haploidentical GVHD was performed at our clinic in children and adolescents with high-risk ALL and AML, at maximal observation terms of 10 years
Mo et al[23], 2016	Internatio nal Journal of Cancer	China	Retrospective comparative	2011-2015	To compare the therapeutic effects of single UCBT and unmanipulated haplo-HSCT in high-risk ALL children
Wang et al[24], 2020	Journal of Internatio nal Clinical Cytometr y Society	China	Prospective cohort	2011-2016	To determine the impact of pre- and post-MRD status as well as peri-transplant MRD kinetics on clinical outcomes focused on children with ALL who received haploidentical allografts
Zhang et al[25], 2022	Chinese Medical Journal	China	Retrospective comparative	2012-2018	To explore the effect of allo- HSCT (especially haploidentical HSCT) on improving survival and reducing relapse for high-risk childhood T-ALL in CR1 and the prognostic factors of childhood T-ALL in order to identify who could benefit from HSCT
Zheng et al[26], 2020	Cancer Communi cations	China	Retrospective comparative	2013-2017	To compare the survival outcomes between high-risk AML children who underwent either unmanipulated HID-SCT or ISD-SCT at three large Chinese SCT centers
Trujillo et al[27], 2021	American Society For Transplan tation and Celular Therapy	Colombia	Retrospective	2012-2017	To decrease the toxicity associated with the addition of 100 mg/kg of cyclophosphamide to a myeloablative regimen while maintaining a good antileukemic effect and a good engraftment rate, using an intermediate-intensity regimen
Yang et al[28], 2022	Hematology	China	Retrospective	2015-2021	To investigate the outcomes and prognostic factors of pediatric AML patients with KMT2A rearrangements who were treated at our institution over a 5-year period
Bai et al[29], 2022	BMC cancer	China	Retrospective	2014-2019	To explore the role of allo- HSCT (especially haploidentical-HSCT) in the treatment of paediatric patients with MLL-r AML in CR1 and investigated the prognostic factors of these patients
Miyamura et al[30], 2019	Leukemia Research	Japan	Retrospective	1988-2011	To investigate the outcomes and prognostic factors of AML with KMT2A rearrangement treated with allogeneic HSCT
Oevermann et al[32], 2014	Blood	Germany	Retrospective comparative	1996-2013	To analyze the influence of KIR haplotypes on the outcome of children with ALL given haploidentical HSCT
Pérez-Martínez et al[33], 2020	American Journal of Hematolo gy	Spain	Retrospective	1999-2016	To compare and analyze the feasibility and outcome of a Spanish cohort of 2 haplo-HSCT platforms in children and adolescents with high-risk hematological malignancies: PT-Cy and ex vivo TCD grafts

JMML: Juvenile myelomonocytic leukemia; HSCT: Hematopoietic stem cell transplantation; PT-Cy: Post-transplantation cyclophosphamide; MUD: Matched unrelated donors; RR-BCP: Relapsed or refractory B-cell precursor acute lymphoblastic leukemia; KIR: Killer cell immunoglobulin-like receptor; TCD: T cells; ALL: Acute lymphocytic leukemia.